{"id":"docetaxel-plinabulin-dp","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Alopecia"}]},"_chembl":{"chemblId":"CHEMBL1096380","moleculeType":"Small molecule","molecularWeight":"336.40"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Docetaxel is a taxane that stabilizes microtubules and prevents cancer cell division. Plinabulin is a vascular disrupting agent that destabilizes microtubules in endothelial cells and immune cells, improving drug delivery to tumors while simultaneously reducing the severity of chemotherapy-induced peripheral neuropathy and neutropenia through immunomodulatory effects on neutrophil function.","oneSentence":"Docetaxel inhibits microtubule depolymerization to arrest cell division, while plinabulin disrupts microtubule dynamics and suppresses neutrophil migration to enhance chemotherapy efficacy and reduce chemotherapy-induced neutropenia.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:11:10.684Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer (Phase 3)"},{"name":"Advanced solid tumors (investigational)"}]},"trialDetails":[{"nctId":"NCT02504489","phase":"PHASE3","title":"Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC","status":"COMPLETED","sponsor":"BeyondSpring Pharmaceuticals Inc.","startDate":"2015-12","conditions":"Non-Small Cell Lung Cancer","enrollment":559}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BPI-2358, NPI-2358"],"phase":"phase_3","status":"active","brandName":"Docetaxel + Plinabulin (DP)","genericName":"Docetaxel + Plinabulin (DP)","companyName":"BeyondSpring Pharmaceuticals Inc.","companyId":"beyondspring-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Docetaxel inhibits microtubule depolymerization to arrest cell division, while plinabulin disrupts microtubule dynamics and suppresses neutrophil migration to enhance chemotherapy efficacy and reduce chemotherapy-induced neutropenia. Used for Metastatic non-small cell lung cancer (Phase 3), Advanced solid tumors (investigational).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}